Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Toggle navigation
Contact Us
Subscribe
Promote Your Event
e-Edition
Privacy Policy
Terms of Service
Local Weather
Home Delivery
Submission Forms
News
Local News
The Leader
Heartland News
Sports
Entertainment
Local Events
Multimedia
Photo Galleries
Videos
Obituaries
Classifieds
Real Estate
Property for Rent
Cars & Vehicles
Jobs
Items for Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place an ad
Legals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arrowhead Pharma
(NQ:
ARWR
)
25.16
-1.09 (-4.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 3, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Arrowhead Pharma
< Previous
1
2
3
4
Next >
Analyst Expectations for Arrowhead Pharma's Future
September 19, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023
September 19, 2023
Via
Benzinga
Cramer Says 'Please Stay Away' From This EV Maker, It 'Should Not Be Public'
September 08, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Norfolk Southern Corporation (NYSE: NSC) is the "cheapest I’ve seen in a very long time,
Via
Benzinga
Analyst Ratings for Arrowhead Pharma
August 08, 2023
Via
Benzinga
Analyst Expectations for Arrowhead Pharma's Future
July 21, 2023
Via
Benzinga
Expert Ratings for Arrowhead Pharma
June 30, 2023
Via
Benzinga
Where Arrowhead Pharma Stands With Analysts
May 24, 2023
Via
Benzinga
The Latest Analyst Ratings for Arrowhead Pharma
May 03, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
July 21, 2023
Via
Benzinga
Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million
June 15, 2023
Eli Lilly inked a deal worth $60 million to get in on a gene-editing drug for elevated lipoprotein A.
Via
Investor's Business Daily
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Via
Investor's Business Daily
Is Arrowhead Pharmaceuticals a Buy Now?
April 16, 2023
The clinical-stage drug developer is attracting a lot of positive attention from investment bank analysts.
Via
The Motley Fool
Expert Ratings for Arrowhead Pharma
April 12, 2023
Via
Benzinga
Arrowhead CEO Christopher Anzalone Addresses The 'Really Important Event' In Lung Disease
June 01, 2023
Arrowhead CEO Christopher Anzalone discusses expectations for ARO-RAGE in lung disease.
Via
Investor's Business Daily
What Arrowhead Pharmaceutical's Interim Data Reveals About A RNAi Therapeutic For Rare Cholesterol Disorder
May 23, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2023
May 12, 2023
Via
Benzinga
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
April 25, 2023
The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.
Via
The Motley Fool
Analyst Ratings for Arrowhead Pharma
March 21, 2023
Via
Benzinga
Arrowhead Pharmaceuticals's Return On Capital Employed Overview
February 07, 2023
Via
Benzinga
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 25, 2023
Gainers
Via
Benzinga
Arrowhead Pharmaceuticals Reveals Data From Healthy Volunteers For Its Asthma Hopeful, Stock Soars
April 25, 2023
Via
Benzinga
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday
April 25, 2023
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 25, 2023
Via
Benzinga
Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward'
April 12, 2023
SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy...
Via
Benzinga
Why Panbela Therapeutics Shares Are Trading Higher By Around 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
April 12, 2023
Gainers TESSCO Technologies Incorporated (NASDAQ: TESS) shares jumped 86.8% to $8.78 as it agreed to be acquired by entities affiliated with Lee Equity Partners and Twin Point Capital for $9.00 in...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2023
April 12, 2023
Via
Benzinga
2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street
April 04, 2023
Arrowhead Pharmaceuticals and Seres Therapeutics are screaming buys, according to some Wall Street analysts.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
March 21, 2023
Via
Benzinga
JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals
February 15, 2023
Via
Benzinga
Why Omeros Are Trading Higher By 32%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 06, 2023
Gainers Secoo Holding Limited (NASDAQ: SECO) jumped 156% to $4.3600. Arqit Quantum Inc. (NASDAQ: ARQQ) gained 41.5% to $3.54.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.